Pharmacodynamics and tolerability of high-dose, prolonged infusion carbapenems in adults with cystic fibrosis - A review of 3 cases

Respiratory Medicine CME

Volumn 3, Issue 3, 2010, Pages 146-149

  Bulik, Catharine C ^a   Quintiliani, Richard ^b   Samuel Pope, J ^a   Kuti, Joseph L ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Burkholderia cepacia; Carbapenem antibiotic meropenem; Cystic fibrosis; Doripenem; Pharmacodynamics; Pharmacokinetics; Pseudomonas aeruginosa

Indexed keywords

COLISTIN; COTRIMOXAZOLE; DORIPENEM; MEROPENEM; TOBRAMYCIN; VANCOMYCIN;

ADULT; ARTICLE; BURKHOLDERIA CEPACIA; CASE REPORT; DRUG BLOOD LEVEL; DRUG MEGADOSE; FEMALE; HUMAN; LUNG FIBROSIS; MALE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

EID: 77954428786     PISSN: 17550017     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmedc.2009.09.011     Document Type: Article

References (23)

1. Gibson R.L., Burns J.L., Ramsey B.W. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003, 168:918-951.
2. Drusano D.L. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 2003, 36(Suppl. 1):S42-S50.
3. Dandekar P.K., Maglio D., Sutherland C.A., Nightingale C.H., Nicolau D.P. Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion. Pharmacotherapy 2003, 23:988-991.
4. Nicasio A.M., Eagye K.J., Nicolau D.P., et al. Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patient with ventilator-associated pneumonia. J Crit Care 2009, 10:1016/j.jcrc.2009.01.014.
5. Elkhaïli H., Niedergang S., Pompei D., Linger L., Leveque D., Jehl F. High-performance liquid chromatography assay for meropenem in serum. J Chromatogr B, Biomed Appl 1996, 686:19-26.
6. Sutherland C., Nicolau D.P. Development of an HPLC method for the determination of doripenem in human and mouse serum. J Chromatogr B, Biomed Appl 2007, 853:123-126.
7. Vinks A.A., Brimicombe R.W., Heijerman H.G., Bakker W. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics. J Antimicrob Chemother 1997, 40:125-133.
8. Rappaz I., Decosterd L.A., Bille J., Pilet M., Belaz N., Roulet M. Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children. Eur J Pediatr 2000, 159:919-925.
9. Kuti J.L., Moss K.M., Nicolau D.P., Knauft R.F. Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patients with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy. Pharmacotherapy 2004, 24:1641-1645.
10. Hayes D., Kanga J.F., Anstead M.I., Kuhn R.J. Novel approach to the eradication of Pseudomonas aerugionsa in an infant with CF after outpatient treatment failure. Pediatr Pulmonol 2008, 43:511-513.
11. Hubert D., Le Roux E., Lavrut T., et al. Continuous versus intermittent infusions of ceftazidime for exacerbation of cystic fibrosis. Antimicrobial Agents Chemother 2009, [epub June 15].
12. Mohr J.F. Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections. Clin Infect Dis 2008, 47:S41-S51.
13. Redman R., File T.M. Safety of intravenous infusion of doripenem. Clin Infect Dis 2009, 49:S28-S35.
14. Horiuchi M., Kimura M., Tokumura M., Hasebe N., Arai T., Abe K. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with β-lactam antibiotics. Toxicology 2006, 222:114-124.
15. Nicolau D.P. Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother 2008, 9:23-37.
16. Bui K.Q., Ambrose P.G., Nicolau D.P., Lapen C.D., Nightingale C.H., Quintiliani R. Pharmacokinetics of high-dose meropenem in adult cystic fibrosis patients. Chemotherapy 2001, 47:153-156.
17. Cirillo I., Vaccaro N., Turner K., Solanki B., Natarajan J., Redman R. Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusion in healthy volunteers. J Clin Pharmacol 2009, 49:798-806.
18. Li C., Kuti J.L., Nightingale C.H., Nicolau D.P. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol 2006, 46:1171-1178.
19. Chastre J., Wunderink R., Prolocimer P., Lee M., Kaniga K., Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008, 36:1089-1096.
20. Pillar C.M., Torres M.K., Brown N.P., Shah D., Sahm D.F. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. Antimicrob Agents Chemother 2008, 52:4388-4399.
21. Van Wart S.A., Andes D.A., Ambrose P.G., Bhavani S.M. Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients. Diagn Microbiol Infect Dis 2009, 63:409-414.
22. Ikawa K., Morikawa N., Ikeda K., Ohge H., Sueda T. Pharmacodynamic assessment of doripenem in peritoneal fluid against gram-negative organisms: use of population pharmacokinetic modeling and Monte Carlo simulation. Diagn Microbiol Infect Dis 2008, 62:292-297.
23. Bhavani S.M., Hammel J.P., Cirincione B.B., Wikler M.A., Ambrose P.G. Use of a pharmacokinetic-pharmacodynamic target attainment analysis to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother 2005, 49:3944-3947.